Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study.

Research output: Contribution to journalArticle


Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Respiratory Medicine and Allergy


  • Cholinergic Antagonists: adverse effects, Carbon Dioxide: blood, Chronic Obstructive: physiopathology, Quality of Life, Vital Capacity, Walking, Chronic Obstructive: drug therapy, Pulmonary Disease, Adrenergic beta-Agonists: adverse effects, Adrenergic beta-Agonists: therapeutic use, Adult, Aged, Bronchodilator Agents: adverse effects, Bronchodilator Agents: therapeutic use, Cholinergic Antagonists: therapeutic use, Comparative Study, Double-Blind Method, Dyspnea: etiology, Ethanolamines: adverse effects, Ethanolamines: therapeutic use, Female, Forced Expiratory Volume, Human, Ipratropium: adverse effects, Ipratropium: therapeutic use, Male, Middle Age, Oxygen: blood, Physical Endurance
Original languageEnglish
Pages (from-to)1138-1146
JournalEuropean Respiratory Journal
Issue number5
Publication statusPublished - 2002
Publication categoryResearch

Bibliographic note

The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Respiratory Medicine and Allergology (013230111), Lung medicine (Malmö) (ceased) (LUR000013), Division of Clinical Chemistry and Pharmacology (013250300)